Angiotech Pharmaceuticals,
Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and
medical device company, announced that the U.S. Food and Sedative
Administration (FDA) has given space to begin marketing the
Hemo-Stream(TM) dyed in the wool dialysis catheter.
The Hemo-Stream catheter, developed by Rex Medical, LP, is the first
chronic hemodialysis catheter specifically designed for over with-the-wire
delivery. Its advantages list higher flow rates payable to its triple lumen
map, reduced covert for air embolism or bleeding, decreased
procedural steps and one day versus competition, and assuage of catheter
placement. Dialysis catheters, such as Hemo-Beck, are used conducive to short term
vascular access to attend to arrange for hemodialysis patients with the dialysis they
require.
In April 2007, Angiotech entered into an compact with Rex Medical
whereby Rex Medical granted Angiotech an sole license to demand and
distribute the Hemo-Tide catheter worldwide.
“The Hemo-Brooklet catheter is a basic complement to the vascular graft
business we acquired from Edwards and our Vascular Wrap AV access trials
which are currently enrolling,” said Dr. William Nimrod, President and CEO
of Angiotech. “With upward of 500,000 End Stage Renal Disease patients in the
U.S., Angiotech is focused on the maturing and commercialization of
innovative dialysis care products that improve the treatment options
at to hemodialysis patients and vascular surgeons.”
It is expected that Hemo-Cataract catheters will be available for
commercial sale in the U.S. later this year.
In all directions Rex Medical, LP
Rex Medical, LP, based in Conshohocken, PA, is a privately held medical
device group specializing in the unfolding, manufacturing and marketing
of minimally invasive medical devices targeted towards the cardiovascular,
venous access, endosurgery and oncology markets.
Note on Advance Looking Statements
Statements contained in this hurry release that are not based on
real fact, including without limitation statements containing the
words “believes,” “may,” “plans,” “will,” “estimate,” “continue,”
“anticipates,” “intends,” “expects” and similar expressions, constitute
“forward-looking statements” within the meaning of the U.S. Reclusive
Securities Legal remedy Reform Act of 1995 and constitute “forward-looking
information” within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the “safe harbor” provisions of
suited securities legislation. Forward-looking statements in this
release categorize but are not narrow to statements anyhow; financial
benefits to Angiotech that could potentially be realized from Angiotech’s
sale of the Hemo-Stream merchandise, the ability of Angiotech to commercialize
the Hemo-Stream product and to develop and commercialize any continual
consequence lines, that a substantial market exists for the product, and that
the spin-off resolve mount as expected. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
induce the actual results, events or developments to be basically different
from any time to come results, events or developments expressed or implied by
such forward-looking statements. Varied such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
into the open-looking statements and include, among others, the following;
general fiscal and business conditions, both nationally and in the
regions in which we handle; market insist on; technological changes that
could hit our existing products or our skills to develop and
commercialize future products; championship; existing governmental
regulations and changes in, or the lemon to comply with, governmental
regulations; decisions, and the timing of decisions, made by health
regulatory agencies regarding approval of our technology and products; the
requirement by reason of substantial funding to conduct probe and maturity and
to expand commercialization activities; and any other factors that may
affect exhibit. In addition, our business is dominate to certain
operating risks that may reason the true to life results expressed or implied by
the forward-looking statements in this report to differ materially from our
factual results. These operating risks take in; poor performance of the
product in the clinical home; adverse events related to the use of the
product; uncalled-for estimate of the extent of the market for the artefact;
adverse results or unexpected delays in clinical development processes; our
ability to attract and impress on the memory talented personnel; our capability faculty to
successfully absolute preclinical and clinical phenomenon of our products;
changes in house procedure or development plans; our failure to be prevalent
patent protection for discoveries; collapse of palpable protection resulting from
third party challenges to our patents; commercialization limitations
imposed by patents owned or controlled by third parties; our ability to
obtain rights to technology from licensors; exposure on patent claims and
other claims asserted against us; our facility to obtain and support timely
patent and other scholar land guardianship into our technology and
products; the ability to enter into, and to maintain, corporate alliances
relating to the maturation and commercialization of our technology and
products; market acceptance of our technology and products; our skill to
successfully manufacture, market and sell our products; the continued
availability of leading to bankroll our activities; and any other factors
referenced in our annual information turn out and other filings with the
applicable Canadian securities regulatory authorities or the SEC.
Given these uncertainties, assumptions and risk factors, readers are
cautioned not to town undue confidence on such brazen-looking statements.
We disclaim any bond to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained in this outline to bring future results, events
or developments.
Hemo-Stream(TM) is a trademark of Rex Medical, LP used under license by
Angiotech.
About Angiotech
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device concern with all through 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for the sake diseases
or complications associated with medical device implants, surgical
interventions and acute outrage. To find out more about Angiotech (NASDAQ:
ANPI, TSX: ANP), suit take in our website at http://www.angiotech.com.
Angiotech Pharmaceuticals, Inc.
http://www.angiotech.com